High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer
Wenwu Xiao(University of California, Davis), Tianhong Li(VA Northern California Health Care System)
Cited by 51
Related Papers
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
|Nature Communications|2022|243
Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models
|Molecular Cancer Therapeutics|2024|8